269 related articles for article (PubMed ID: 26469159)
1. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
Kobiyama K; Ishii KJ
Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159
[TBL] [Abstract][Full Text] [Related]
2. [Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma].
Katsuda M; Iwahashi M; Matsuda K; Miyazawa M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):1942-4. PubMed ID: 22202246
[TBL] [Abstract][Full Text] [Related]
3. Use of adjuvants for immunotherapy.
Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
Vollmer J; Krieg AM
Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
[TBL] [Abstract][Full Text] [Related]
5. TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens.
Shirota H; Klinman DM
Methods Mol Biol; 2014; 1139():337-44. PubMed ID: 24619691
[TBL] [Abstract][Full Text] [Related]
6. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
7. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.
Shima F; Uto T; Akagi T; Akashi M
Bioconjug Chem; 2013 Jun; 24(6):926-33. PubMed ID: 23631730
[TBL] [Abstract][Full Text] [Related]
8. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy.
Liang Z; Cui X; Yang L; Hu Q; Li D; Zhang X; Han L; Shi S; Shen Y; Zhao W; Ju Q; Deng X; Wu Y; Sheng W
Int J Pharm; 2021 Oct; 608():121091. PubMed ID: 34555477
[TBL] [Abstract][Full Text] [Related]
9. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.
Silva A; Mount A; Krstevska K; Pejoski D; Hardy MP; Owczarek C; Scotney P; Maraskovsky E; Baz Morelli A
J Immunol; 2015 Mar; 194(5):2199-207. PubMed ID: 25646304
[TBL] [Abstract][Full Text] [Related]
10. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
Banday AH; Jeelani S; Hruby VJ
Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
[TBL] [Abstract][Full Text] [Related]
11. TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice.
Yildirim M; Yildirim TC; Turay N; Bildik T; Ibibik B; Evcili I; Ersan PG; Tokat UM; Sahin O; Gursel I
Immunol Lett; 2021 Nov; 239():32-41. PubMed ID: 34418488
[TBL] [Abstract][Full Text] [Related]
12. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.
Wang J; Zhang W; He A; Zhao W; Cao X
Oncol Rep; 2011 Feb; 25(2):519-29. PubMed ID: 21165566
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
[TBL] [Abstract][Full Text] [Related]
14. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
Hamdy S; Haddadi A; Hung RW; Lavasanifar A
Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
Butt AQ; Mills KH
Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
[TBL] [Abstract][Full Text] [Related]
16. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
Jahrsdörfer B; Weiner GJ
Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
[TBL] [Abstract][Full Text] [Related]
17. Adjuvants for cancer vaccines.
Dubensky TW; Reed SG
Semin Immunol; 2010 Jun; 22(3):155-61. PubMed ID: 20488726
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy: moving forward with peptide T cell vaccines.
Kumai T; Fan A; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
[TBL] [Abstract][Full Text] [Related]
19. [Cancer immunotherapy with CpG-ODN].
Carpentier AF
Med Sci (Paris); 2005 Jan; 21(1):73-7. PubMed ID: 15639024
[TBL] [Abstract][Full Text] [Related]
20. Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.
Zhang W; An M; Xi J; Liu H
Bioconjug Chem; 2017 Jul; 28(7):1993-2000. PubMed ID: 28644608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
